Evotec SE ADR Total Liabilities
Evotec SE ADR total liabilities. Based on the latest financial reports, Evotec SE ADR (EVO) has total liabilities worth $941.17 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Evotec SE ADR (EVO) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Evotec SE ADR (2003–2025)
Total liabilities of Evotec SE ADR from 2003 to 2025. This chart illustrates how Evotec SE ADR's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Evotec SE ADR to see how much of total assets are deployed in long-term investments.
Evotec SE ADR Competitors by Total Liabilities
The table below lists competitors of Evotec SE ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lotte Corp
KO:004990
|
Korea | ₩13.76 Trillion |
|
Yuanta Futures Co Ltd
TWO:6023
|
Taiwan | NT$295.55 Billion |
|
ABOUT YOU Holding AG
F:YOU
|
Germany | €902.70 Million |
|
Hannstar Display Corp
TW:6116
|
Taiwan | NT$9.58 Billion |
|
Cymbria Corporation
TO:CYB
|
Canada | CA$138.94 Million |
|
Cibus Nordic Real Estate AB (publ)
ST:CIBUS
|
Sweden | Skr1.85 Billion |
|
El Puerto de Liverpool S.A.B. de C.V
MX:LIVEPOLC-1
|
Mexico | MX$124.59 Billion |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
Taiwan | NT$168.08 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Evotec SE ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EVO asset base.
Liquidity & Leverage Metrics
Evotec SE ADR Total Liabilities Ratios Explained
Evotec SE ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evotec SE ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evotec SE ADR (2003–2025)
The table below shows the annual total liabilities of Evotec SE ADR from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $964.64 Million | +0.49% |
| 2024-12-31 | $959.98 Million | -18.59% |
| 2023-12-31 | $1.18 Billion | +10.19% |
| 2022-12-31 | $1.07 Billion | +24.79% |
| 2021-12-31 | $857.48 Million | -9.86% |
| 2020-12-31 | $951.26 Million | +12.66% |
| 2019-12-31 | $844.39 Million | +143.34% |
| 2018-12-31 | $347.00 Million | +3.42% |
| 2017-12-31 | $335.52 Million | +144.14% |
| 2016-12-31 | $137.43 Million | +35.47% |
| 2015-12-31 | $101.44 Million | +53.20% |
| 2014-12-31 | $66.22 Million | -3.21% |
| 2013-12-31 | $68.41 Million | -6.13% |
| 2012-12-31 | $72.88 Million | +2.69% |
| 2011-12-31 | $70.97 Million | +19.83% |
| 2010-12-31 | $59.22 Million | +68.67% |
| 2009-12-31 | $35.11 Million | +6.27% |
| 2008-12-31 | $33.04 Million | -11.48% |
| 2007-12-31 | $37.33 Million | -45.39% |
| 2006-12-31 | $68.35 Million | +82.55% |
| 2005-12-31 | $37.44 Million | +307.75% |
| 2004-12-31 | $9.18 Million | +61.18% |
| 2003-12-31 | $5.70 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more